Cost-effectiveness of amiodarone in cardiac surgery

Area of Science:

• Cardiology
• Health Economics
• Pharmacoeconomics

Background:

• Postoperative atrial fibrillation (POAF) is a common complication following open-heart surgery, affecting 25-50% of patients.
• POAF increases hospital length of stay and associated healthcare costs.

Purpose of the Study:

• To review and synthesize findings from economic studies evaluating amiodarone prophylaxis for POAF prevention in cardiac surgery patients.
• To assess the cost-effectiveness and impact on length of stay of amiodarone prophylaxis.

Main Methods:

• Systematic review and meta-analysis of over 15 economic studies, including randomized controlled trials, naturalistic studies, and economic models.
• Pooled data from multiple meta-analyses (6-19 amiodarone trials) to determine the effect on POAF incidence.
• Analysis of cost-neutrality and impact on length of stay as primary economic endpoints.

Main Results:

• Four meta-analyses demonstrated a significant reduction in POAF incidence with amiodarone prophylaxis (odds ratio range: 0.50-0.54).
• A majority of studies indicated that amiodarone prophylaxis is cost-neutral.
• Amiodarone prophylaxis was associated with a decreased length of hospital stay, a key cost driver for POAF.

Conclusions:

• Amiodarone prophylaxis is effective in reducing the incidence of postoperative atrial fibrillation after cardiac surgery.
• The intervention is generally cost-neutral and can reduce healthcare costs by shortening hospital stays.
• Selective use in high-risk patients (e.g., >70 years, prior AF, COPD, concurrent valve surgery) may further enhance cost-effectiveness.